Profound Medical Corp · TSX:PRN
Profound Medical — AUA 2025 Investor Event
88 slides from Profound Medical's conference presentation, Apr 29, 2025
Slide 1: Profound Medical AUA 2025 Investor Event
PROFGUND | TULSA-PRO’ PROFOUND MEDICAL AUA 2025 INVESTOR EVENT
Slide 2: Establishing TULSA-PRO as the Mainstream Treatment Option for Personalized Prostate Ablation
Establishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer • CAPTAIN Level 1 randomized controlled trial, peri - operative data and patient experience • Dr. Ram Pathak’s TULSA experience, outcomes and effici
Slide 3: Robotic Prostatectomy Adoption was Driven by Patient Demand
Robotic Prostatectomy Adoption was Driven by Patient Demand Prospective, multi - center, comparative but not randomized No difference in prostate cancer outcomes • Same rate of positive surgical margins (20% robotic vs 16% open; not significant) No difference in health related QOL • Same decline in
Slide 4: CAPTAIN Peri-operative Outcomes Complete Established Clinical Evidence
CAPTAIN Peri - operative Outcomes Complete Established TULSA - PRO Clinical Evidence of Cancer Outcomes and Favorable QOL TACT FDA Study + Real - World Usage + Review Articles Patient Experience Head - to - head RCT to SOC Health related QOL Whole & Partial Gland Prostate Cancer 5 - year Outcomes TU
Slide 5: CAPTAIN Randomized Controlled Trial (NCT05027477)
CAPTAIN Randomized Controlled Trial (NCT05027477) • Practice guidelines and commercial payors call for Level 1 RCTs to establish ablative therapies as SOC • Past RCTs for localized Pca failed to recruit due to lack of equipoise (SPIRIT, SWOG - 8890, START, etc ) • CAPTAIN is the first RCT in this sp
Slide 6: Principal Investigators Include the Best Academic and Private Surgeons
Principal Investigators Include the Best Academic and Private Surgeons Dr. Naveen Kella Dr. Preston Sprenkle, Dr. Sandeep Arora Dr. Brant Inman , Dr. Joseph Chin Dr. Laurence Klotz Dr. Rahul Mehan Dr. Kia Michel Dr. Robert Princenthal, Dr. Martin Cohen Dr. Ruben Olivares Dr. Yair Lotan, Dr. Xiaosong
Slide 7: Eliminates Blood Loss & Overnight Stay for the Patient & Hospital
TULSA - PRO Eliminates Blood Loss & Overnight Stay for the Patient & Hospital Median (IQR) Treatment 0 (0 – 0) mL TULSA 100 (100 – 200) mL RP Median (IQR) Treatment 0.29 (0.27 – 0.32) d TULSA 1.24 (1.12 – 1.36) d RP p < 0.001 p < 0.001 From less blood loss to No blood loss From shorter length of sta
Slide 8: Improves Post-treatment Patient Experience
TULSA - PRO Improves Post - treatment Patient Experience 0% 3% 17% 8% 4% 12% 17% 40% 15% 3% 0% 10% 20% 30% 40% 50% TULSA RP EQ - 5D - 5L Health Status after treatment (% reporting extreme problem / inability) NRS pain scale after treatment (0 “no pain” to 10 “worst pain imaginable”) p=0.001 p=0.005
Slide 9: Patients are in Better Overall Health After Treatment
TULSA - PRO Patients are in Better Overall Health After Treatment 0 = ‘The best health you can imagine’ 100 = ‘The worst health you can imagine’ Significantly better overall health during first month post treatment Change in EQ - 5D - 5L VAS overall health score after treatment Significantly less de
Slide 10: Clinical Outcomes Lead to High Patient Satisfaction
TULSA - PRO Clinical Outcomes Lead to High Patient Satisfaction Which will Drive Patient Demand and TULSA - PRO Adoption UT SW TULSA Treatment Satisfaction REDCap survey completed by 96 patients Primary & salvage from Oct ’20 – Dec ‘23 Urinary sx , sexual fx and decision regret scale Decision Regret
Slide 11: Established & Increasing Clinical Evidence Continue to Validate TULSA
Established & Increasing Clinical Evidence Continue to Validate TULSA Review of all prostate ultrasound (and IRE) ablation publications from the U.S.
Slide 12: Unrivaled Precision Technology & Ablation Flexibility
Unrivaled Precision Technology & Ablation Flexibility Targeted ablation of extreme apical lesion Transition Zone ablation for BPH Salvage hemi for radio - recurrent PCa BPH + increased PCa ablation identified on treatment - day DWI Fiducial Markers Lesion at apex level TZ - only ablation Lesion exte
Slide 13: Summary
Summary • CAPTAIN randomized trial of TULSA vs. radical prostatectomy is the first RCT of a new technology in localized prostate cancer to successfully recruit to target • CAPTAIN peri - operative outcomes demonstrate that TULSA has no blood loss and no overnight stay, along with statistically signi
Slide 14: Prostate cancer ablation using MRI-guided transurethral ultrasound: How I do it
Prostate cancer ablation using MRI - guided transurethral ultrasound (TULSA - PRO): How I do it Ram A. Pathak, MD Associate Professor Vice - Chair of Research, Department of Urology P.E.D. Mayo Clinic Comprehensive Cancer Center R.A.D. Mayo Clinic Alix School of Medicine Mayo Clinic Florida
Slide 15: Disclosures
Disclosures Funding sources: • Blue Earth Diagnostics: IIT. Imaging in Prostate Cancer • Samaritan Biologics: IIT. Use of stem - cell biologics in nerve - sparing radical prostatectomy Advisory Board: • Ambu
Slide 16: MRI-Guided Transurethral Ultrasound Ablation of the Prostate
MRI - Guided Transurethral Ultrasound Ablation of the Prostate (TULSA - PRO) Transurethral ultrasound: • Incision and needle - free • No energy through rectum • Any region & size of prostate Real - time MRI robotics, with AI: • AI - assisted treatment planning • Physician - controlled robotics • Clo
Slide 17: Patient Pathway
TULSA - PRO PATIENT PATHWAY Follow - up Catheter removal visit (1 week) Post - op follow - up (PSA, QOL, recovery at 1, 3, 6, 9, 12 months) 12 - month MRI ± biopsy Long - term follow - up (PSA, QoL every 6 months, MRI every 12 months) New Diagnosis Outside Referral Initial Consult and Workup Review
Slide 18: Patient Selection
TULSA - PRO PATIENT SELECTION • ISUP Grade Group 2 or 3, preferably MRI - concordant • Select ISUP 1 (high PSAD, % pos cores, MRI - visible lesion, adverse genomics, seeking treatment for obstructive BPH) • Recurrent prostate cancer seeking local salvage after prior radiation or ablation • Treatment
Slide 19: Shared Decision-Making
SHARED DECISION - MAKING • Plan treatment based on patient’s priorities and goals (focal vs. subtotal, sparing nerves / apex / bladder neck) New Diagnosis Outside Referral Initial Consult and Workup Review history, function, biopsy, MRI, staging, CT Workup Multidisciplinary review by focal therapy t
Slide 20: Treatment
TULSA - PRO TREATMENT Interventional MRI surgical suite at Mayo Florida:
Slide 21: Treatment: Applicator Insertion
TULSA - PRO TREATMENT TULSA ultrasound applicator insertion: • Insert Foley catheter • Drain bladder • Insert guidewire • Remove Foley • Insert ultrasound applicator over guidewire • Remove guidewire • Dock UA to TULSA robot
Slide 22: Treatment Planning
TULSA - PRO TREATMENT PLANNING
Slide 23: Case Example: Anterior GG2 Lesion
CASE EXAMPLE: ANTERIOR GG2 LESION • PSA 7.6 ng/ml, Grade Group 2, Anterior PI - RADS 5 at mid to base • 46cc gland, 2 posterior calcifications on screening CT • Focal anterior ablation, 2 sweeps (sparing nerves, ejaculatory ducts) • UA placed centrally, 26mm target radius, ice cooling of UA fluid li
Slide 24: Post-op and Follow-up
POST - OP AND FOLLOW - UP • Immediate post - op care: • Pain / anti - inflammatory: Toradol • Catheter removal visit at 1 week • Antibiotics: single dose at catheter removal • Temporary, if any, stress incontinence • Penile rehab • Follow - up: • PSA / IIEF / EPIC / IPSS every 3 months for first yea
Slide 25: Post-op Urinary Changes
POST - OP Urinary Changes • 76 y/o Male with significant voiding symptoms preoperatively; PSA 20.3 • Right Anterior TZ lesion • GG3, 60% ROI, systematics negative • Whole gland TULSA was performed for combined treatment of cancer plus BPH Cystoscopy video provided courtesy of Dr. Chandler Dora
Slide 26: TULSA Workflow: Timing Diagram
TULSA WORKFLOW: TIMING DIAGRAM Planning Anesthesia Ablation Pre - op Post - op TULSA QA Room ready Anesthesia & Positioning Alignment Coarse Detailed Planning Start Angle Post scan, UA removal Patient Transfer Device Insertion Device Repositioning Initialization Treating Paused Review Device Inserti
Slide 27: TULSA Workflow: Timing Diagram
TULSA WORKFLOW: TIMING DIAGRAM • Total MRI time (room turnover plus treating physician time) consistently improving 0 1 2 3 4 5 6 Total MRI Time (h) Patient number
Slide 28: Workflow: Cases Per Day
TULSA - PRO WORKFLOW: 3 CASES PER DAY • Significant workflow improvements in room prep / turnover times: • Consistent team of TULSA MRI technologists, prep TULSA kit for next case when ablation begins • Anesthesia team works in parallel with techs and urology, internal anesthesia wiki keeps all prov
Slide 29: Real-world outcomes after MRI-guided transurethral ultrasound ablation
Real - world outcomes after MRI - guided transurethral ultrasound ablation of the prostate in a multicenter post - market registry Ram Pathak, Chandler Dora, Xiaosong Meng, Naveen Kella, Adnaan S Moin, Edward Steiner, Martin Cohen, Robert Princenthal, Yair Lotan, Kenneth Goldberg, Daniel Costa, Davi
Slide 30: Customized Ablation Registry (CARE)
Customized TULSA - PRO Ablation Registry (CARE, NCT05001477) GG1 14% GG2 62% GG3 19% GG4 5% Histological Grade (Primary PCa) n=223 Focal 18% Hemi 9% Subtotal 33% Whole - gland 40% n=223 Ablation Fraction (Primary PCa) Primary PCa 80% PCa+BPH 17% Radio - recurrent PCa 3% HIFU recurrent Pca <1% n=230
Slide 31: Efficacy Outcomes
Efficacy Outcomes • 141 patients reached 1 - year follow - up • PSA decreased 90% (IQR 77 - 96%) • 75% had no evidence of disease on follow - up MRI at 6 - 24 months • By ≥1 year, 9% had biopsy - confirmed ≥GG2 disease, 7% had GG1 • Additional PCa treatment in 6.3% (2.8% EBRT, 3.5% repeat TULSA) PSA
Slide 32: Safety and Functional Outcomes
Safety and Functional Outcomes At ≥ 1 year: • 94% pad - free, 98% leak - free (EPIC) • 77% preserved erectile function (IIEFQ2≥2) • 15% reported erectile dysfunction ( Clavien - Dindo) • 4% had GU complications requiring endoscopic / surgical correction AUA 2025, Pathak et al. TULSA CARE Registry
Slide 33: Conclusions
CONCLUSIONS • Initial experience at first US academic site outside of clinical trials demonstrates benefits of TULSA especially when used for subtotal ablation • TULSA - PRO offered alongside surgery and radiation for intermediate - risk PCa • Outcomes prospectively tracked in CARE registry demonstr
Slide 34: Incision-Free Ablative Intervention With Vision
Incision - Free Ablative Intervention With Vision TULSA – AI Contouring Assistant, FDA cleared in May 2024 Introducing TULSA - AI Volume Reduction: 1. Volume Customizer 2. Treatment ARC Potential to Treat Patients with Symptoms of BPH or ablate lesion targeted sub - total gland (focal) Corporate Pr
Slide 35: Prostate Diseases: Tripling TAM
Prostate Diseases • Tripling TULSA - PRO TAM: • Ablation of malignant prostate tissue; approximately 200,000 patients per year • Ablation of tissue due to BPH; approximately 400,000 patients per year • Total TAM approximately $ 5 B, about 70% in recurring revenue • TULSA Day: Surgeons plan a
Slide 36: TULSA-AI Intelligent modules with a purpose
TULSA - AI Intelligent modules with a purpose • Improve Clinical Outcomes • Reduce Treatment Time • Improve Workflow • Further Improve Ease Of Use • Increase Applicability Of TULSA To Variety Of Patients TULSA - AI modules include: 1. Thermal Boost – increases heat to the outer edge
Slide 37: TULSA-AI Volume Reduction: Volume Customizer and Treatment Arc
TULSA - AI Volume Reduction Uses Two New Features: Volume Customizer and the Treatment Arc A fast and simple way to ablate any sub - total region of the prostate for relief from BPH symptoms TZ TZ TZ TZ Treatment Arc Volume Customizer Today, with AI based Contouring Assistant Adding Volume Customize
Slide 38: TULSA-AI Lesion Targeted Ablation
TULSA - AI Lesion Targeted Ablation Uses Contouring Assistant and Treatment Arc TZ TZ TZ TZ Prescribe Treatment Arc for lesion - targeted ablation PCa lesion
Slide 39: TULSA-AI Efficient Personalized Treatment Plans for Cancer and BPH
TULSA - AI Efficient Personalized Treatment Plans for Patients With Cancer and BPH Prostate Cancer Ablation TULSA - AI Contouring Assistant Benign Prostate Ablation TULSA - AI Volume Reduction
Slide 40: TULSA-AI Volume Reduction Demo
TULSA - AI Volume Reduction Demo
Slide 41: TULSA-AI Volume Reduction for Relief of BPH Symptoms
TULSA - AI Volume Reduction for Relief of BPH Symptoms - 5 BPH cases/day
Slide 42: 92% Volume Reduction with TULSA
92% Volume Reduction with TULSA - PRO • TACT pivotal trial, n = 115 • Perfused prostate volume decreased 92% from 37 cc to 3 cc, on MRI at 1 year 1. Klotz et al, J Urol 2020
Slide 43: TULSA-AI Volume Reduction Launch Plan
TULSA - AI Volume Reduction Launch Plan Positioning for patients with larger prostates and or higher PSA’s that create suspicion of cancer Clinical data collection with CARE registry
Slide 44: TULSA-AI Volume Reduction: Rapid ablation of large prostate volume
TULSA - AI Volume Reduction Rapid ablation of large prostate volume • No overnight stay • No blood loss, no fulguration • No history of Grade 4 Adverse Events • No need to discontinue anti - coagulants • Treat any region including anterior, customizable • Same indication for use, reimbursement codes
Slide 45: Prostate Ablation in men with Lower Urinary Tract Symptoms
Prostate Ablation in men with Lower Urinary Tract Symptoms Naveen Kella, MD Founder of The Urology Place, San Antonio TX
Slide 46: Disclosures
Disclosures 46 Clinical advisory board for Profound Medical Investigator in the CAPTAIN randomized trial *All guest speakers’ presentations reflect the medical views and experience of the physicians and are not attributable to Profound Medical.
Slide 47: Treatments for Lower Urinary Tract Symptoms (LUTS)
Treatments for Lower Urinary Tract Symptoms (LUTS) • Voiding and storage urinary symptoms caused by benign prostatic hyperplasia (BPH) affect most men as they age, including men who also have low - risk prostate cancer • Treatment options for obstructive BPH: • Behavioral changes, medications, tempo
Slide 48: TULSA for Alleviation of Lower Urinary Tract/BPH Symptoms
TULSA for Alleviation of Lower Urinary Tract/BPH Symptoms • Proven to safely ablate large volumes of both benign and malignant prostate tissue (TACT study, >90% prostate volume reduction at one year after whole - gland treatment) • TULSA addresses limitations of other volume - reducing BPH treatment
Slide 49: Early evidence on TULSA for BPH
Early evidence on TULSA for BPH
Slide 50: Prospective Phase I-II Study of TULSA for Men with BPH
Prospective Phase I - II Study of TULSA - PRO for Men with BPH • Single - center study of symptom relief after TULSA in 30 men with LUTS due to BPH • Transition zone ablation, including intravesical median lobes, sparing normal peripheral zone and neurovascular bundles • Ablation time: 43 (IQR 24 -
Slide 51: Prospective Phase I-II Study of TULSA for Men with BPH
Prospective Phase I - II Study of TULSA - PRO for Men with BPH Viitala et al, BJU International 2021. Anttinen et al, EAU 2022, AUA 2024. Baseline (n=28) 3 mo (n=28) 6 mo (n=28) 9 mo (n=24) 12 mo (n=24) 24 mo (n=7) 0 5 10 15 20 25 30 35 IPSS Symptom Score Baseline (n=28) 3 mo (n=28) 6 mo (n=28) 9 mo
Slide 52: TULSA Phase I-II Study in Context
TULSA Phase I - II Study in Context Peak flow ( Qmax , ml/s) Bother (IPSS QoL) Symptoms (IPSS) + Δ 12m T=0 - Δ 12m T=0 - Δ 12m T=0 N Treatment 13.8 21.2 7.4 2.7 1.4 4.1 (65%) 14.0 7.6 21.6 1083 TURP 14.5 22.5 8.0 3.3 1.2 4.5 (66%) 15.6 8.1 23.7 100 Laser TURP (Greenlight) 4.0 12.1 8.1 2.3 2.2 4.5 (4
Slide 53: BPH Case Study
BPH Case Study PROFOUND
Slide 54: Transition Zone Ablation for LUTS in 106 cc Gland
Transition Zone Ablation for LUTS in 106 cc Gland Case Study using previous TULSA - PRO software: • Age 58, 106 cc gland, 2x neg biopsy, taking tamsulosin and tadalafil for urgency and high PVR • Patient prioritized preserving urinary, sexual, and ejaculatory function; refused RASP and Aquablation •
Slide 55: What will be the Sweet Spot for TULSA as a BPH Treatment?
What will be the Sweet Spot for TULSA - PRO as a BPH Treatment? Procedure duration (min) Prostate volume (cc) 30 80 150 180 120 0 RASP PAE 60 TULSA - PRO with TULSA - AI Volume Reduction
Slide 56: Conclusions
Conclusions • TULSA - PRO achieves lasting LUTS relief in large prostates through significant prostate volume reduction leading to symptom and uroflowmetry improvements comparable to resection • Anterolateral treatment plans using MRI targeting of TZ spare neurovascular bundles, ejaculatory ducts, v
Slide 57: TULSA+ program business model, benefits, targets and commercial plans
Incision - Free Ablative Intervention With Vision TULSA+ program business model, benefits, targets and commercial plans Corporate Presentation | April 2025 © 2024 Profound Medical Corp. NASDAQ: PROF, TSX: PRN
Slide 58: The Era Of Interventional MR is Here
The Era Of Interventional MR is Here, Driven By Patient Demand for Fast Recovery, No Blood Loss, and AI Based High Precision Treatment • 40 - year trend towards less invasive procedure • MR based treatment procedures are flexible enough to treat a wide variety of patients • No blood loss, no
Slide 59: Society Guidelines Supporting MRI in Prostate Cancer
Society Guidelines Supporting MRI in Prostate Cancer
Slide 60: Combining TULSA + MR to Create a Complete Interventional Suite
Combining TULSA + MR to Create a Complete Interventional Suite for Personalized and Precise Ablative Procedures Robotic Prostatectomy iMRI Suite • Demanded by patients and surgeon • Reduced blood loss, reduced hospital stay • Hospitals established robotic suites • First widely used applica
Slide 61: Paving the Way for the Future: Interventional MRI Suite
Paving the Way for the Future: Interventional MRI Suite
Slide 62: MR Centered Prostate Treatment Pathway Managed by Urologists
MR Centered Prostate Treatment Pathway Managed by Urologists Screening Lesion Detection Targeted Biopsy Staging Treatment Follow - Up bpMRI mpMRI Cognitive, Fusion, or In - bore MRI detection of EPE, SVI MRI - guided ablation with TULSA - PRO PI - RR, PI - FAB, TARGET
Slide 63: What is TULSA+?
What is TULSA+? MRI Workflow optimization Profound Genius Services Patient, Physician, Staff education Economics iMRI Solution + =
Slide 64: MAGNETOM Free.Max 0.55T for Interventional Procedures
MAGNETOM Free.Max 0.55T – Particularly Suitable for Interventional Procedures and Breaking Barriers to Expand the Reach of MRI Providing greater flexibility to offer MR services and open up new clinical opportunities *Courtesy of Siemens
Slide 65: Redefining MRI Affordability with MAGNETOM Free.Max
Redefining MRI Affordability with MAGNETOM Free.Max *Courtesy of Siemens
Slide 66: Prostate Imaging on Siemens MAGNETOM Free.Max with AI Deep Resolve
Prostate Imaging on Siemens MAGNETOM Free.Max with AI Deep Resolve Conventional Deep Resolve *Courtesy of Siemens
Slide 67: A Complete Solution for Any Site of Service
A Complete Solution for Any Site of Service *Courtesy of Siemens
Slide 68: Reimbursement Across All Channels
Reimbursement Across All Channels TULSA - PRO Facility Teaching Hospital Community Hospital ASC LUGPA Non - Facility (OBL) Imaging Center (non - IDTF) Physicians Office LUGPA
Slide 69: Opens Up MRI Feasibility in Urology
TULSA - PRO Opens Up MRI Feasibility in Urology TULSA - PRO Procedures Only MRI Diagnostic Procedures Only 2 60 Weekly 8 239 Monthly 99 2,862 First Year *Example: ASC in Chicago, IL *50% Medicare / 50% Private Insurance Cashflow Positive
Slide 70: Opens Up MRI Feasibility in Urology
TULSA - PRO Opens Up MRI Feasibility in Urology • 2 - 4 TULSA per day, 1 day per week • 7 Dx scans MRI patients per day remainder of the week • Includes monthly capital lease costs, construction, service, FTE, and marketing • Conservative patient mix: • 50% Medicare • 50% Private Insura
Slide 71: Growth Opportunity with TULSA
Growth Opportunity with TULSA - PRO 68 CTs 6 PVPs 76 Consults >200 Lab Orders 34 PSMA PET/CTs 30 Biopsies 8 INR 8 Stress Tests 40 EKG 8 Cardiac Evaluation 40 Pre - Op Evaluations 78 MRIs *Actual case volumes and additional procedures from TULSA - PRO Center provided as an example
Slide 72: Convergence of Market Dynamics Will Create Transformative Growth
Convergence of Market Dynamics Will Create Transformative Growth
Slide 73: Commercial Organization
Commercial Organization PROFOUND: + VP, Sales + VP, Business + National Director of * Directors of Sales Development & Market Development Regional Busi Strategy Market Development + Regional Business , ,, © Directors Director of Strategic Directors , Partnerships & * Capital Sales Government Sales *
Slide 74: Commercial Team: The Core
PROFCGUND- Commercial Team: The Core 4 ADOPTION
Slide 75: The Evolution of Prostate Surgery: What Has Changed?
The Evolution of Prostate Surgery: What Has Changed? Y Mark Hong, MD Integrative Urology, Phoenix Arizona
Slide 76: Disclosures
Disclosures 76 Clinical advisory board for Profound Medical *All guest speakers’ presentations reflect the medical views and experience of the physicians and are not attributable to Profound Medical.
Slide 77: Technology Life Cycle
Technology Life Cycle R&D Ascent|Maturty] Decline © Business Gain Traditional Technology Life-Cycle Curve INTEGRATIVE” URGZOGY
Slide 78: Technology Adoption Curve
Technology Adoption Curve Performance ——> INTEGRATIVE” URGZOGY Technological limit Effort ——> Performance ——» Limit B Limit A Technology B Discontinuity Technology A Effort ——»>
Slide 79: Evolution of Prostate Surgery
Evolution of Prostate Surgery • Open nerve - sparing modern robotic prostatectomy • Elusive goal of durable outcomes, urinary continence & sexual function
Slide 80: Robotics Era: What has changed?
Robotics Era: What has changed? Did the robot improve quality of clinical care? Summary: • Clinical outcomes of prostatectomy have not improved in over 30 years • Robotics have helped reduce acute surgical incision complications but have not improved the core of the problem for patients which is HRQ
Slide 81: Alternative Therapies
Alternative Therapies • QOL considerations give rise to Active Surveillance • Patient demand pushes the door open for alternative and focal therapies • Concern for durability limits adoption
Slide 82: Outcomes
TULSA - PRO Outcomes • TACT trial: 115 men, low & intermediate - risk prostate cancer • 75% PSA reduction or more at 12 - month follow - up • Among 68 intermediate - risk men, 79% free of ≥GG2 disease at 12 - month prostate biopsy • Biochemical recurrence - free survival of 85% at 5 years • 87% repo
Slide 83: Looking Forward
Looking Forward • Open nerve - sparing modern robotic prostatectomy • Robotic surgery improved blood loss and length of stay; No difference in urinary incontinence, erectile dysfunction, decision regret • Recurrences after surgery or radiation have limited curative options
Slide 84: Will TULSA become the Standard of Care?
Will TULSA - PRO become the Standard of Care? • Robotic surgery improved blood loss and length of stay. No difference in urinary incontinence, erectile dysfunction, decision regret. • Recurrences after surgery or radiation have limited curative options. • TULSA - PRO outcomes in TACT and real - worl
Slide 85: Building a Successful Program
Building a Successful TULSA - PRO Program Location • Hospital vs. Imaging Center • Availability of MRI time and anesthesia support • Layout and equipment of MRI suite Team • Consistent and motivated anesthesia, nurse, technologist Patient Selection • Independently motivated to undergo TULSA - PRO •
Slide 86: Anatomy of a TULSA Day
Anatomy of a 5 - TULSA - PRO day • Methodical workflow, not rushed. • Entire team remains focused on patient care. • Minimize anesthesia time to reduce risk of complications. • Communication: Between physician, anesthesia, technologist. • Well - defined roles allow steps to be performed in parallel.
Slide 87: Building the Future of iMRI
TULSA - PRO and Building the Future of iMRI • TULSA+ creates an all - in - one solution for an outfitted MRI suite enabling the intervention MRI suite • Expanded capabilities with TULSA - PRO for Cancer and BPH treatment • CAPTAIN will provide the first comparative evidence for TULSA - PRO vs. RALP
Slide 88: Paving the Way for the Future: Interventional MRI Suite
Paving the Way for the Future: Interventional MRI Suite Cardiovascular Neuro Urology Gastroenterology Spine Prostate Brain Spine Cardiovascular Pancreas Adenomyosis